EMG
GLMD icon

Ellington Management Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Ellington Management Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-62
Closed -$96K – 585
2014
Q3 		$96K Buy
+62
New +$84.8K 0.07% 269

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return

Ellington Management Group's GLMD Position: Q4 2014 in Review

Ellington Management Group sold out of Galmed Pharmaceuticals (GLMD) in Q4 2014, closing a stake of 62 shares — an estimated $96K sold.

Ellington Management Group first reported a position in GLMD in Q3 2014 and held it in 1 quarter. The position peaked at $96K in Q3 2014. 16 funds tracked by Wall St. Rank hold GLMD as of Q4 2014.

  • Ellington Management Group reported no remaining Galmed Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Ellington Management Group sold 62 Galmed Pharmaceuticals shares in Q4 2014, an estimated $96K.
  • Ellington Management Group first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Ellington Management Group's Galmed Pharmaceuticals position peaked at $96K in Q3 2014.
  • 16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2014.

Based on Ellington Management Group's 13F filing for Q4 2014, filed 17 Feb 2015.